MY197429A - Afucosylated antibodies and manufacture thereof - Google Patents
Afucosylated antibodies and manufacture thereofInfo
- Publication number
- MY197429A MY197429A MYPI2021000708A MYPI2021000708A MY197429A MY 197429 A MY197429 A MY 197429A MY PI2021000708 A MYPI2021000708 A MY PI2021000708A MY PI2021000708 A MYPI2021000708 A MY PI2021000708A MY 197429 A MY197429 A MY 197429A
- Authority
- MY
- Malaysia
- Prior art keywords
- afucosylated
- antibodies
- afucosylated antibodies
- host cell
- producing
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 230000033581 fucosylation Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01068—Glycoprotein 6-alpha-L-fucosyltransferase (2.4.1.68), i.e. FUT8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/102995 WO2020042015A1 (en) | 2018-08-29 | 2018-08-29 | Afucosylated antibodies and manufacture thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY197429A true MY197429A (en) | 2023-06-16 |
Family
ID=69642839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021000708A MY197429A (en) | 2018-08-29 | 2018-08-29 | Afucosylated antibodies and manufacture thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210317499A1 (enExample) |
| EP (1) | EP3818149A4 (enExample) |
| JP (1) | JP7216806B2 (enExample) |
| KR (1) | KR102596303B1 (enExample) |
| CN (1) | CN113166728A (enExample) |
| AU (1) | AU2018438767B9 (enExample) |
| BR (1) | BR112021003765A2 (enExample) |
| CA (1) | CA3110254C (enExample) |
| MY (1) | MY197429A (enExample) |
| SG (1) | SG11202101099PA (enExample) |
| WO (1) | WO2020042015A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202101102UA (en) * | 2018-08-29 | 2021-03-30 | United Biopharma Inc | Afucosylated antibodies and manufacture thereof |
| EP4243860A4 (en) * | 2020-11-13 | 2024-10-16 | iBio, Inc. | ANTI-CD25 ANTIBODIES |
| WO2022261021A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| CN113684322B (zh) * | 2021-09-09 | 2024-01-23 | 上海药明生物技术有限公司 | 一种降低抗体类蛋白高聚甘露糖型水平的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
| EP1498485A4 (en) * | 2002-04-09 | 2006-09-06 | Kyowa Hakko Kogyo Kk | MODIFIED GENOME CELLS |
| EP1888638A2 (en) * | 2005-06-03 | 2008-02-20 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
| WO2008090958A1 (ja) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | ドメイン交換された遺伝子組換え抗体組成物 |
| CN102459603B (zh) * | 2009-06-02 | 2013-11-06 | 瑞泽恩制药公司 | 岩藻糖基化缺陷型细胞 |
| US8469819B2 (en) * | 2009-06-04 | 2013-06-25 | Michael Parker McMain | Game apparatus and game control method for controlling and representing magical ability and power of a player character in an action power control program |
| AU2011222012C1 (en) | 2010-03-02 | 2015-02-26 | Kyowa Kirin Co., Ltd. | Modified antibody composition |
| AU2012226398B9 (en) | 2011-03-06 | 2017-04-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
| IL217216A0 (en) * | 2011-12-27 | 2012-07-31 | Merck Serono Sa | Low fucose cell lins and uses thereof |
| JP6796773B2 (ja) * | 2014-07-30 | 2020-12-09 | ツムトー バイオロジクス、インコーポレイテッド | 非フコシル化タンパク質および方法 |
| WO2017079165A1 (en) * | 2015-11-02 | 2017-05-11 | Genentech, Inc. | Methods of making fucosylated and afucosylated forms of a protein |
| CN106167525B (zh) * | 2016-04-01 | 2019-03-19 | 北京康明百奥新药研发有限公司 | 筛选超低岩藻糖细胞系的方法和应用 |
| CN106701823A (zh) * | 2017-01-18 | 2017-05-24 | 上海交通大学 | 生产无岩藻糖单克隆抗体的cho细胞系建立及其应用 |
| CN107881160A (zh) * | 2017-08-11 | 2018-04-06 | 百奥泰生物科技(广州)有限公司 | 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法 |
-
2018
- 2018-08-29 CA CA3110254A patent/CA3110254C/en active Active
- 2018-08-29 WO PCT/CN2018/102995 patent/WO2020042015A1/en not_active Ceased
- 2018-08-29 BR BR112021003765-9A patent/BR112021003765A2/pt not_active IP Right Cessation
- 2018-08-29 JP JP2021511628A patent/JP7216806B2/ja active Active
- 2018-08-29 MY MYPI2021000708A patent/MY197429A/en unknown
- 2018-08-29 KR KR1020217007804A patent/KR102596303B1/ko active Active
- 2018-08-29 AU AU2018438767A patent/AU2018438767B9/en not_active Ceased
- 2018-08-29 SG SG11202101099PA patent/SG11202101099PA/en unknown
- 2018-08-29 CN CN201880096956.2A patent/CN113166728A/zh active Pending
- 2018-08-29 US US17/270,987 patent/US20210317499A1/en not_active Abandoned
- 2018-08-29 EP EP18931397.6A patent/EP3818149A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN113166728A (zh) | 2021-07-23 |
| EP3818149A4 (en) | 2022-03-23 |
| AU2018438767B9 (en) | 2023-10-05 |
| AU2018438767A1 (en) | 2021-04-01 |
| US20210317499A1 (en) | 2021-10-14 |
| EP3818149A1 (en) | 2021-05-12 |
| KR20210047316A (ko) | 2021-04-29 |
| AU2018438767B1 (enExample) | 2023-07-13 |
| JP2021534801A (ja) | 2021-12-16 |
| WO2020042015A1 (en) | 2020-03-05 |
| KR102596303B1 (ko) | 2023-10-30 |
| CA3110254A1 (en) | 2020-03-05 |
| SG11202101099PA (en) | 2021-03-30 |
| BR112021003765A2 (pt) | 2021-05-25 |
| JP7216806B2 (ja) | 2023-02-01 |
| CA3110254C (en) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY197429A (en) | Afucosylated antibodies and manufacture thereof | |
| PH12020500368A1 (en) | B7-h4 antibodies and methods of use thereof | |
| PH12018501282A1 (en) | Anti-c5 antibodies and methods of use | |
| TW200621980A (en) | Anti-glypican 3 antibody having modified sugar chain | |
| NZ630568A (en) | Methods and means for the production of ch3 domain-comprising molecules | |
| MX2015017110A (es) | Integracion dirigida. | |
| IN2012DN01769A (enExample) | ||
| MY183415A (en) | Anti-c5 antibodies and methods of use | |
| BR112018002214A2 (pt) | ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho? | |
| NZ597334A (en) | Cell culture improvements | |
| PH12012501833A1 (en) | Manufacturing method for sugar solution and device for same | |
| SG196836A1 (en) | Cancer stem cell population and method for production thereof | |
| EP4026901A3 (en) | Method for screening alpha-amylases | |
| PH12015501837B1 (en) | Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins | |
| EP4502167A3 (en) | N-glycosylation | |
| WO2010128024A3 (en) | Reversibly immortalized cells as well as methods relating hereto | |
| MY181513A (en) | Cell culture compositions and methods for polypeptide production | |
| NZ611862A (en) | Animal cell culturing method | |
| NZ715246A (en) | Improved process for production of monoclonal antibodies | |
| IN2014CN03196A (enExample) | ||
| BR112022012109A2 (pt) | Célula de levedura capaz de produzir e8,e10-dodecadienil coenzima a e opcionalmente e8,e10-dodecadien-1-ol, e, método para produzir e8,e10-dodecadienil coenzima a e opcionalmente e8,e10-dodecadien-1-ol em uma célula de levedura | |
| BR112022009836A2 (pt) | Método para fornecer células imunes com função aumentada | |
| EP4234704A3 (en) | Recombinant cell and production method for isoprene | |
| MX338560B (es) | Enzimas de fusion que tienen actividad de n-acetilglucosaminil transferasa. | |
| EP4446338A3 (en) | Cells and method of cell culture |